![Stefan Pflanz](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Stefan Pflanz
Direttore/Membro del Consiglio presso
TigaTx, Inc.
Profilo
Stefan Pflanz currently works at Boehringer Ingelheim (Venture Capital), as Executive Director from 2020, Bodyport, Inc., as Director, and TigaTx, Inc., as Director.
Posizioni attive di Stefan Pflanz
| Società | Posizione | Inizio |
|---|---|---|
Boehringer Ingelheim (Venture Capital)
 Boehringer Ingelheim (Venture Capital) Investment ManagersFinance BIVF invests in companies located across the globe including the United States, Europe and China. The firm targets companies operating in groundbreaking innovation including cancer, regenerative medicine, auto-immunity indications, digital solutions and infectious disease. It participaotes in seed and early stage capital requirements. The firm acquires minority interest and makes follow-on investments. It also takes seat on the board of directors. | Investitore di Private Equity | 01/01/2020 |
Bodyport, Inc.
 Bodyport, Inc. Packaged SoftwareTechnology Services Publishes mobile applications which provides blood pressure, heart rate and other health information | Direttore/Membro del Consiglio | - |
TigaTx, Inc.
 TigaTx, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that develops engineered immunoglobulin to create isotype cancer antibody | Direttore/Membro del Consiglio | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
41
Relazioni di 1° grado
3
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 3 |
|---|---|
Boehringer Ingelheim (Venture Capital)
Boehringer Ingelheim (Venture Capital) Investment ManagersFinance BIVF invests in companies located across the globe including the United States, Europe and China. The firm targets companies operating in groundbreaking innovation including cancer, regenerative medicine, auto-immunity indications, digital solutions and infectious disease. It participaotes in seed and early stage capital requirements. The firm acquires minority interest and makes follow-on investments. It also takes seat on the board of directors. | Finance |
Bodyport, Inc.
Bodyport, Inc. Packaged SoftwareTechnology Services Publishes mobile applications which provides blood pressure, heart rate and other health information | Technology Services |
TigaTx, Inc.
TigaTx, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that develops engineered immunoglobulin to create isotype cancer antibody | Health Technology |
